Parallel Advisors’s Albany Molecular Research Inc AMRI Stock Holding History

Parallel Advisors’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-216	Closed	-$5K	–	2339
2017 Q2	$5K	Buy	216 +66	+44%	+$1.2K	﹤0.01%	1638
2017 Q1	$2K	Hold	150	–	–	﹤0.01%	1835
2016 Q4	$3K	Buy	+150	New	+$2.55K	﹤0.01%	1580

Other funds holding AMRI

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Parallel Advisors's AMRI Position: Q3 2017 in Review

Parallel Advisors sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 216 shares — an estimated $5K sold.

Parallel Advisors first reported a position in AMRI in Q4 2016 and held it in 3 quarters. The position peaked at $5K in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

Parallel Advisors reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
Parallel Advisors sold 216 Albany Molecular Research Inc shares in Q3 2017, an estimated $5K.
Parallel Advisors first reported a position in Albany Molecular Research Inc in Q4 2016 and held it in 3 quarters.
Parallel Advisors's Albany Molecular Research Inc position peaked at $5K in Q2 2017.
2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Parallel Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.